This meta-analysis pooled 16 studies and 1.78 million patients, comparing SGLT2 inhibitors with other glucose-lowering agents for progression of diabetic retinopathy and macular oedema. The scale is its strength; its observational design is the caveat.
SGLT2 inhibitors were associated with lower diabetic retinopathy progression (relative risk 0.77, 95% CI 0.72 to 0.82) and macular oedema progression (0.75, 0.69 to 0.82) versus other agents, with the largest advantage over sulfonylureas and a softer difference against GLP-1 receptor agonists. The benefit tracked baseline risk: in cohorts with a 20% retinopathy rate, the absolute reduction was around 4%.
Ophthalmologists do not prescribe these drugs, but they influence the conversation. For a patient with established retinopathy whose diabetes team is choosing between agents, this supports favouring an SGLT2 inhibitor over a sulfonylurea, other things being equal — and it is worth a line in the clinic letter back to the physician.
- SGLT2 inhibitors linked to ~23% less retinopathy progression (RR 0.77) and ~25% less DME progression
- Clearest advantage over sulfonylureas; weaker versus GLP-1 receptor agonists
- Absolute benefit larger where baseline retinopathy risk is higher (~4% at 20% rate)
- Support an SGLT2 inhibitor in the systemic conversation for patients with established eye disease
The statistics, in plain English
A relative risk of 0.77 means SGLT2-inhibitor users had 77% of the retinopathy-progression risk of comparators — a 23% relative reduction; the interval (0.72 to 0.82) is tight and below 1.0, reflecting the enormous sample. But these are observational cohorts, so unmeasured differences between who gets which drug could inflate the apparent benefit; treat it as strong association, not proof of cause.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free